Efficacy Results for LOXO-101 in TRK Fusion Cancers

June 3, 2017
David Hyman, MD

David Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.